Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAV | P06756 | 20/20 | 0.81 |
| ▸ | ITGB3 | P05106 | 18/20 | 0.81 |
| ▸ | ITGB6 | P18564 | 6/20 | 0.74 |
| ▸ | ITGB8 | P26012 | 4/20 | 0.74 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.70 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.70 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.70 |
| ▸ | ITGB5 | P18084 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22209127 | 1.00 | ITGAV (0.81) | ITGAVITGB3ITGB6ITGB8ITGA2B | |
| SCHEMBL22223362 | 1.00 | ITGAV (0.81) | ITGAVITGB3ITGB6ITGB8ITGA2B | |
| SCHEMBL6433019 | 0.90 | ITGAV (0.78) | ITGAVITGB3ITGB6ITGB8ITGA2B | |
| SCHEMBL6432148 | 0.90 | ITGAV (0.78) | ITGAVITGB3ITGB6ITGB8ITGA2B | |
| SCHEMBL6432259 | 0.90 | ITGAV (0.78) | ITGAVITGB3ITGB6ITGB8ITGA2B | |
| SCHEMBL29883175 | 0.90 | ITGAV (0.71) | ITGAVITGB3ITGB6ITGB8ITGA2B | |
| SCHEMBL22223449 | 0.90 | ITGAV (0.71) | ITGAVITGB3ITGB6ITGB8ITGA2B | |
| SCHEMBL22223258 | 0.90 | ITGAV (0.71) | ITGAVITGB3ITGB6ITGB8ITGA2B | |
| SCHEMBL22223270 | 0.90 | ITGAV (1.00) | ITGAVITGB3ITGB6ITGB8ITGA2B | |
| SCHEMBL18029415 | 0.89 | ITGAV (0.78) | ITGAVITGB3ITGB6ITGB8ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3784269-B1 | INTEGRIN TARGETING LIGANDS AND USES THEREOF | ARROWHEAD PHARMACEUTICALS INC (US) | 2024-06-05 | — | — | EP | disclosed |
| US-20220204976-A1 | RNAi Agents for Inhibiting Expression of HIF-2 alpha (EPAS1), Compositions Thereof, and Methods of Use | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2022-06-30 | — | — | US | disclosed |
| EP-3908288-A2 | RNAI AGENTS FOR INHIBITING EXPRESSION OF HIF-2 ALPHA (EPAS1), COMPOSITIONS THEREOF, AND METHODS OF USE | Arrowhead Pharmaceuticals, Inc. (US) | 2021-11-17 | — | — | EP | disclosed |
| US-20210093725-A1 | INTEGRIN TARGETING LIGANDS AND USES THEREOF | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2021-04-01 | — | — | US | disclosed |
| WO-2020146521-A2 | RNAI AGENTS FOR INHIBITING EXPRESSION OF HIF-2 ALPHA (EPAS1), COMPOSITIONS THEREOF, AND METHODS OF USE | Arrowhead Pharmaceuticals, Inc. (US) | 2020-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210093725-A1 | INTEGRIN TARGETING LIGANDS AND USES THEREOF | ITGAV, ITGA5, ITGB5 | ITGAV 1/4885ITGB3 4/4885ITGB6 17/4885 |
| US-20220204976-A1 | RNAi Agents for Inhibiting Expression of HIF-2 alpha (EPAS1), Compositions Thereof, and Methods of Use | EPAS1, HIF1AN, HIF1A | ITGAV 7/4885ITGB3 10/4885ITGB6 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.